Re Exercise of Warrants

ReNeuron Group plc
14 December 2006

                        RESULTS OF EXERCISE OF WARRANTS



Guildford, UK, 14 December 2006: ReNeuron Group plc (LSE: RENE) today announces
that the Company has raised approximately £1.9 million from the proceeds of the
exercise of Warrants to purchase Ordinary Shares in the Company at a price of 10
pence per share.



A total of 18,919,400 Ordinary Shares will be issued on 19 December 2006 in
respect of the exercise of the Warrants (representing the exercise of 99.6% of
the total number of Warrants).



The Warrants were originally issued in connection with the initial public
offering of the Company in August 2005.



Application has been made to the AIM market of the London Stock Exchange plc to
admit such Ordinary Shares to trading with effect from 8:00 am on 19 December
2006. The total issued share capital of the Company following such issue will be
118,524,100 Ordinary Shares.



The Company will not be appointing a trustee in respect of the small number of
unexercised Warrants, which have lapsed and ceased to be exercisable by the
holders thereof.



Michael Hunt, Chief Executive Officer of ReNeuron, said:



'We are delighted to have raised the proceeds available to us from the warrants.
This has further bolstered the Company's cash resources as we look towards 
approval of our recently filed application to commence human clinical studies 
with our lead ReN001 stem cell therapy for stroke.'



Enquiries:


ReNeuron
Michael Hunt, CEO                                       Tel: [phone]


Financial Dynamics
David Yates                                             Tel: [phone]
Nicola Daley





Notes to Editors



ReNeuron is a leading, UK-based adult stem cell therapy business.  It is
applying its novel stem cell platform technologies in the development of
ground-breaking stem cell therapies to serve significant and unmet or poorly-met
clinical needs.



ReNeuron has used its c-mycERTAM technology to generate genetically stable
neural stem cell lines.  This technology platform has multi-national patent
protection and is fully regulated by means of a chemically-induced safety
switch.  Cell growth can therefore be completely arrested prior to in vivo
implantation.



ReNeuron has filed for approval to commence initial clinical studies in the US
with its lead ReN001 stem cell therapy for chronic stroke disability.  This
represents the world's first such filing concerning a neural stem cell treatment
for a major neurological disorder.  There are an estimated 50 million stroke
survivors worldwide, approximately one half of which are left with permanent
disabilities.



ReNeuron has also generated pre-clinical efficacy data with its ReN005 stem cell
therapy for Huntington's disease, a genetic and fatal neurodegenerative disorder
that affects around 1 in 10,000 people.  This programme is in pre-clinical
development.



In addition to its stroke and Huntington's disease programmes, ReNeuron is
developing stem cell therapies for Parkinson's disease, Type 1 diabetes and
diseases of the retina.



ReNeuron has also leveraged its stem cell technologies into non-therapeutic
areas - its ReNcellTM range of cell lines for use in research and in drug
discovery applications in the pharmaceutical industry.  ReNeuron's ReNcellTM CX
and ReNcellTM VM neural cell lines are marketed worldwide under license by
Millipore Corporation.



ReNeuron's shares are traded on the London AIM market under the symbol RENE.L.



Further information on ReNeuron and its products can be found at
www.reneuron.com.



Data sources: UK Stroke Association, American Stroke Association.



This announcement contains forward-looking statements with respect to the
financial condition, results of operations and business achievements/performance
of ReNeuron and certain of the plans and objectives of management of ReNeuron
with respect thereto. These statements may generally, but not always, be
identified by the use of words such as 'should', 'expects', 'estimates',
'believes' or similar expressions. This announcement also contains
forward-looking statements attributed to certain third parties relating to their
estimates regarding the growth of markets and demand for products. By their
nature, forward-looking statements involve risk and uncertainty because they
reflect ReNeuron's current expectations and assumptions as to future events and
circumstances that may not prove accurate.  A number of factors could cause
ReNeuron's actual financial condition, results of operations and business
achievements/performance to differ materially from the estimates made or implied
in such forward-looking statements and, accordingly, reliance should not be
placed on such statements.



The terms 'ReNeuron', 'the Company' or 'the Group' used in this statement refer
to ReNeuron Group plc and/or its subsidiary undertakings, depending on the
context.




                      This information is provided by RNS
            The company news service from the London Stock Exchange